|
Age
|
64 ± 12
|
59 ± 11
|
0.037
|
|
Male, n (%)
|
14 (53.8)
|
67 (61.5)
|
0.624
|
|
Body mass index (kg/m2)
|
26.1 ± 5.7
|
25.3 ± 4.3
|
0.396
|
|
Smoking, n (%)
|
3 (11.5)
|
19 (17.4)
|
0.567
|
|
Hypertension, n (%)
|
18 (69.2)
|
56 (51.4)
|
0.154
|
|
Diabetes mellitus, n (%)
|
7 (26.9)
|
39 (35.8)
|
0.531
|
|
Previous CABG, n (%)
|
9 (34.6)
|
34 (31.2)
|
0.918
|
|
Ejection fraction, %
|
32 (25–55)
|
34 (20–55)
|
0.210
|
|
COPD, n (%)
|
3 (11.5)
|
16 (14.7)
|
1.0
|
|
Hemoglobin, g/dL
|
13.2 (10.8–15.1)
|
12.8 (9.5–14.5)
|
0.946
|
|
Platelet count, K/mm3
|
239 ± 69
|
246 ± 55
|
0.630
|
|
BUN, mg/dL
|
30.2 (25–39)
|
31.6 (22–45)
|
0.975
|
|
Creatinine, mg/dL
|
1.0 ± 0.4
|
1.1 ± 0.4
|
0.614
|
|
Atrial fibrillation, n (%)
|
10 (38.5)
|
33 (30.3)
|
0.568
|
|
Metallic prosthetic valve, n (%)
|
11 (42.3)
|
43 (39.4)
|
0.964
|
|
LV thrombus, n (%)
|
4 (15.4)
|
5 (4.6)
|
0.069
|
|
Recent stent implantation, n (%)
|
23 (88.5)
|
40 (36.7)
|
<0.001
|
|
Medications
|
|
ACEI/ARB, n (%)
|
22 (84.6)
|
73 (67.0)
|
0.126
|
|
Beta blocker, n (%)
|
24 (92.3)
|
88 (80.7)
|
0.245
|
|
Diuretic, n (%)
|
21 (80.8)
|
78 (71.6)
|
0.479
|
|
Spironolactone, n (%)
|
19 (73.1)
|
48 (44.0)
|
0.015
|
|
Statin, n (%)
|
13 (50.0)
|
49 (45.0)
|
0.807
|
|
Warfarin, n (%)
|
4 (15.4)
|
68 (62.4)
|
<0.001
|
|
DAPT, n (%)
|
7 (26.9)
|
30 (27.5)
|
1.0
|
|
Warfarin plus DAPT, n (%)
|
15 (57.7)
|
11 (10.1)
|
<0.001
|
